Study of the Drug B11-FC (Botulism Treatment)
Phase 1
Not yet recruiting
- Conditions
- Botulism
- Interventions
- Drug: B11-FCOther: PlaceboDrug: Botulinum neurotoxin type A
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 40
- Registration Number
- NCT06580236
The Surveillance Clinical Study of Rickettsiosis
Recruiting
- Conditions
- Rickettsiosis
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 100
- Registration Number
- NCT06162975
- Locations
- 🇷🇺
Altai Republic Center for HIV prophylaxis and treatment, Gorno-Altaïsk, Altai Republic, Russian Federation
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
Phase 2
Not yet recruiting
- Conditions
- Gram Negative PneumoniaGram-Negative Bacterial InfectionsBacteremia Caused by Gram-Negative Bacteria
- Interventions
- Other: PlaceboDrug: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 234
- Registration Number
- NCT06135350
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
Phase 1
Not yet recruiting
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Drug: Glycolic acid tetrasubstituted piceatannol (TGKP)
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 25
- Registration Number
- NCT06127381
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 50
- Registration Number
- NCT06068569
Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 50
- Registration Number
- NCT06068556
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 50
- Registration Number
- NCT06057025
Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus
Phase 2
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Drug: GamCoviMab
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 30
- Registration Number
- NCT05729360
HIV A6 Genome In ART Unsuccessful Patients On DOR
- Conditions
- Virus-HIV
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 60
- Registration Number
- NCT05322083
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
Phase 1
- Conditions
- SARS-CoV-2 Acute Respiratory DiseaseCOVID-19
- Interventions
- Biological: Gam-COVID-VacOther: Placebo
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 400
- Registration Number
- NCT05248373
© Copyright 2025. All Rights Reserved by MedPath